Probiotic-drug interactions in ulcerative colitis: a microbiota and metabolite perspective
This narrative review maps pharmacokinetic and pharmacodynamic mechanisms by which probiotics may modify drug efficacy in ulcerative colitis, but provides no quantified effect estimates nor definitive clinical evidence grade.
| Population | Adult patients with ulcerative colitis on conventional pharmacotherapy |
|---|---|
| Intervention | Co-administration of probiotics (any strain or formulation) |
| Comparator | Conventional pharmacotherapy without probiotics |
| Outcome | Clinical remission (mild-to-moderate UC); Pharmacokinetic modification (AUC of co-administered drugs); Gut microbiota composition; Short-chain fatty acid (SCFA) production; Epithelial barrier integrity; Mucosal immune response (pro-inflammatory cytokines); Safety and adverse effects of co-administration |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Clinical remission (mild-to-moderate UC) | narrative synthesis only; in the pooled effect size or 95% CI reported | — | Low | — | |
| Pharmacokinetic modification (AUC of co-administered drugs) | preclinical only; AUC increase reported for amiodarone (E. coli Nissle 1917, rats) and AUC decrease for acetaminophen (L. reuteri K8, mice); in the human UC data, in the 95% CI | — | Very low | — | 2 studies |
| Gut microbiota composition | narrative synthesis only; in the quantified effect size or 95% CI | — | Very low | — | |
| Short-chain fatty acid (SCFA) production | mechanistic/narrative only; in the quantified effect size | — | Very low | — | |
| Epithelial barrier integrity | mechanistic/preclinical only; in the quantified clinical effect size | — | Very low | — | |
| Mucosal immune response (pro-inflammatory cytokines) | mechanistic/narrative only; in the pooled effect size or 95% CI | — | Very low | — | |
| Safety and adverse effects of co-administration | not formally assessed; in the safety data reported | — | Very low | — |
Context
Ulcerative colitis affects approximately 120 cases per 100,000 people and requires chronic treatment; therapeutic failure and loss of response are common. The pharmacomicrobiomics field investigates how gut microbiota alters drug pharmacokinetics and pharmacodynamics — a bidirectional interaction relevant when probiotics are co-administered with aminosalicylates, corticosteroids, immunomodulators, or biologics.
What the study showed
This is a narrative review systematizing mechanistic and preclinical evidence on probiotic-drug interactions. No quantified effect estimates from UC-specific randomized clinical trials are reported. Animal model data indicate that E. coli Nissle 1917 and Lacticaseibacillus casei increased systemic amiodarone exposure in rats; L. reuteri K8 reduced acetaminophen AUC in mice — neither finding directly translatable to UC. The most consistent UC evidence cited supports E. coli Nissle 1917 and the De Simone formulation for induction and maintenance of remission in mild-to-moderate disease, drawing on previously published studies without original meta-analysis.
How it was done
Narrative review published in Frontiers in Microbiology (2026). No registered protocol, no explicit systematic search strategy in the provided text, no standardized study selection. Includes preclinical models, clinical trials from non-IBD conditions, and observational UC studies. Aggregate sample size is not reported.
Effect magnitude
No effect size with 95% CI is calculated for clinical outcomes in UC. Cited preclinical data (AUC modifications for amiodarone and acetaminophen) are not directly extrapolable to the target population.
Risk of bias
Narrative review without registered protocol; no formal risk of bias assessment (RoB 2, ROBINS-I, or AMSTAR-2 tools not applied). High heterogeneity across strains, formulations, and clinical conditions precludes quantitative synthesis. Most mechanistic evidence derives from animal models or non-UC conditions. Publication bias not assessed. No explicit inclusion/exclusion criteria.
What this study does NOT prove
This study does not prove that probiotics clinically alter the efficacy or safety of any specific UC drug in humans. It does not establish causality between probiotic strains, metabolic modifications, and clinical outcomes in ulcerative colitis.
In clinical practice
Clinicians should recognize that probiotics co-administered with UC drugs may theoretically alter bioavailability and immune response, but this review does not provide sufficient clinical evidence to modify therapeutic protocols. E. coli Nissle 1917 and the De Simone formulation have the most consistent support as adjuncts in mild-to-moderate UC based on previously cited studies. Individualized clinical monitoring remains necessary.
Limitations
Narrative review without registered protocol; no formal risk of bias assessment (RoB 2, ROBINS-I, or AMSTAR-2 tools not applied). High heterogeneity across strains, formulations, and clinical conditions precludes quantitative synthesis. Most mechanistic evidence derives from animal models or non-UC conditions. Publication bias not assessed. No explicit inclusion/exclusion criteria.
What is still missing
Randomized clinical trials specifically designed to evaluate pharmacokinetic and pharmacodynamic interactions between defined probiotic strains and UC drugs are needed. Pharmacomicrobiomics studies in UC with primary clinical endpoints and validated microbiota measures do not yet exist.
Technical appendix
Version history
- 1.0 · 2026-11-13 — Auto-generated under Evidence Standard v1.0